Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 12,928 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07368998RecruitingPhase 2
Study of inavolisib plus fulvestrant for advanced breast cancer
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07363057RecruitingPhase 2
Study of GI-102 and GIB-7 for aging in healthy adults and cancer survivors
This trial tests whether a combination of two drugs, GI-102 and GIB-7, can affect markers of aging in healthy people and in people who have had cancer. It aims to see if these drugs might help slow or improve aging-related changes.
Charlestown, New South WalesAges 18–80 - NCT06847555RecruitingPhase 1/Phase 2
Taurine cream to prevent skin burns from radiation in breast cancer
This trial tests if a taurine cream applied to the skin can prevent or reduce the painful skin reactions caused by radiation therapy for breast cancer. It may offer a simple way to protect your skin during treatment.
Jinan, ShandongAges 18 years+ - NCT03957902RecruitingPhase 2
Aspirin blood markers to guide prevention after colon cancer
This Phase 2 trial studies how aspirin affects specific “biomarkers” (measurable body signals) in people newly diagnosed with colon or rectal cancer. The goal is to see whether aspirin-related changes can help design more personalized prevention treatment plans.
Zaragoza, ZaragozaAges 18–79 - NCT05057052RecruitingPhase 2
Freezing liver tumors with immunotherapy and a pill drug
This Phase 2 trial tests whether freezing (cryoablation) plus sintilimab (an immune system medicine) and regorafenib (a pill) can shrink colorectal cancer that has spread to the liver. It is for people whose cancer has come back or progressed after at least two prior chemotherapy treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05319639RecruitingPhase 1/Phase 2
Irinotecan plus immunotherapy for stomach cancer
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
Fuzhou, FujianAges 18–75 - NCT05384509Recruiting
Tracking antibody levels in cancer patients during COVID vaccines
This study measures COVID “neutralizing” antibodies over time in people with cancer who are on different kinds of cancer treatments. It aims to understand how vaccination and treatment type affect immune protection in cancer patients.
New Taipei CityAges 20 years+ - NCT06703632Recruiting
Testing a new stool test for early colon cancer detection
This study is evaluating PreveCol, a new second-line stool test for people aged 50–69 who had a positive FIT/FOBT result and are already scheduled for a colonoscopy. It aims to find out if this test can help detect colorectal cancer earlier.
Lisbon, Lisbon DistrictAges 50–69 - NCT06783829RecruitingPhase 1
Study of SHR-4394 for men with advanced prostate cancer
This trial tests a new drug, SHR-4394, for men with prostate cancer that has spread to other parts of the body and is no longer responding to current treatments. The goal is to see if this drug can help slow down the cancer.
Chengdu, SichuanAges 18–85 - NCT06421324Recruiting
AI-guided health advice for stomach conditions
This trial tests whether a personalized AI program can give you better health advice based on your stomach condition. It is for people who have gastric intestinal metaplasia (GIM) or have had H. pylori infection and are already scheduled for a gastroscopy.
ValenciaAges 18 years+ - NCT07357207Enrolling by invitation
Video-immunotherapy for advanced breast cancer
This trial tests if a video-based immunotherapy approach can help treat locally advanced breast cancer. It is designed for people who can communicate in Turkish and are comfortable playing video games as part of their treatment.
Izmir, BalcovaAges 18 years+ - NCT06692972Recruiting
How lung cancer tumors change after high-dose radiation
This study looks at how the main lung tumor shrinks or changes after a complete course of high-dose radiation in people with stage II or III lung cancer. It uses scans taken before and after treatment to track the results.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07361497RecruitingPhase 3
New Drug vs Standard Drug After Chemoradiation for Stage 3 Lung Cancer
This study tests a new drug, pumitamig, against an older drug, durvalumab, for people with stage 3 non-small cell lung cancer that cannot be removed by surgery and has not progressed after chemotherapy and radiation. The goal is to see which drug works better to keep the cancer from growing.
Daphne, AlabamaAges 18 years+ - NCT07356531Recruiting
Thermosensitive Embolic Agent for Liver Cancer TACE
This trial tests a new heat-sensitive embolic agent used during TACE (a procedure that blocks blood flow to tumors and delivers chemotherapy directly to the liver) for primary liver cancer. It aims to see if the agent is safe and effective for patients who need TACE treatment.
Hefei, AnhuiAges 18–80 - NCT07354711RecruitingPhase 1/Phase 2
Study of 3H-10000 for advanced solid tumors
This trial tests a new drug called 3H-10000 for people with solid tumors that cannot be removed by surgery or have spread. The goal is to see if it is safe and works against cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07361003RecruitingPhase 3
Testing suvemcitug plus chemo for refractory colorectal cancer
This trial tests a new drug, suvemcitug, combined with an oral chemotherapy called FTD/TPI for people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07358377RecruitingPhase 1
Combination therapy for HR-positive, HER2-negative cancer
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
Bowral, New South WalesAges 18 years+ - NCT06763029RecruitingPhase 2
Study of three drugs for advanced colorectal cancer after first treatment
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06849167RecruitingPhase 2
Immunotherapy with low-dose chemoradiation for advanced lung cancer
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
BeijingAges 18–70 - NCT06850545Recruiting
Lu-177 treatment for PSMA-positive metastatic prostate cancer
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
Kuopio, Northern SavoniaAges 18 years+ - NCT07361471Recruiting
Ovarian cancer genetics: comparing platinum response groups
This study looks at genetic and other factors that may explain why some people with ovarian cancer respond well to platinum-based chemotherapy for many years, while others do not respond at all. The goal is to better understand these differences to improve future treatments.
Clermont-Ferrand, PUY DE DOMEAges 18 years+ - NCT07361614Recruiting
Colorectal cancer education program
This study tests a program to help people learn about colorectal cancer screening. If you are 45 to 75 and due for screening, you may be able to join.
New York, New YorkAges 45–75
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 12,928 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.